AzTrials
AzTrials

Diabetic Nephropathy Type 2NCT07498894

Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status

An observational study of Diabetic Nephropathy Type 2 and Type 2 Diabetes, run by Pamukkale University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Chronic inflammation underlies the bidirectional relationship between diabetes and periodontitis, a process that may be further exacerbated in the presence of diabetic nephropathy. Read more about this study

Who is it for?
Ages 20 to 75 years
What is being tested?
clinical periodontal measurements, serum samples and saliva samples
How many people
126 participants
Where
1 siteTurkey (Türkiye)
Study dates
10 Jun 2024to 12 Dec 2025
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Newly diagnosed type 2 diabetic subjects were recruited from patients diagnosed with type 2 diabetes for less than 5 years attending the outpatient clinic of the Department of Endocrinology, Pamukkale University Hospital and subsequently referred to the Department of Periodontology. Following periodontal examination, participants were diagnosed as periodontally healthy, gingivitis, or periodontitis, and were allocated to the corresponding study groups according to their periodontal status.

Who may be able to join

  • Newly diagnosed diabetes: Diagnosed with type 2 diabetes mellitus for less than 5 years and the absence of any diabetic vascular complications
  • Diabetic nephropathy: Urinary albumin-to-creatinine ratio >30 mg/g

Who cannot join

  • Having fewer than 15 natural teeth
  • Pregnancy or lactation
  • History of malignancy
  • Use of systemic antibiotics or anti-inflammatory drugs within the 6 months prior to study enrollment
  • Periodontal treatment within the previous 6 months
  • Type 1 diabetes mellitus, gestational diabetes mellitus, or secondary diabetes mellitus

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Pamukkale University Faculty of Dentistry

    Denizli, 20160

Other trials in Turkey (Türkiye)

About this study

Official title: Salivary and Serum Inflammatory Biomarkers Based on Periodontal Status in Individuals With Diabetic Nephropathy

Chronic inflammation underlies the bidirectional relationship between diabetes and periodontitis, a process that may be further exacerbated in the presence of diabetic nephropathy. While the roles of inflammatory cytokines such as TNF-α and IL-10 in both periodontal tissue destruction and diabetes-related microvascular complications remain unclear, NGAL is recognized as a biomarker for diabetic nephropathy but its association with periodontal disease is not well established. This study aimed to comparatively evaluate salivary and serum levels of NGAL, TNF-α, and IL-10 according to different periodontal conditions in individuals with newly diagnosed diabetes and those with diabetic nephropathy.

Read the detailed description

The newly diagnosed diabetes mellitus group consisted of patients attending the Department of Endocrinology who had been diagnosed with type 2 diabetes mellitus for less than 5 years and had no evidence of diabetic vascular complications. The diabetic nephropathy group comprised patients followed in the Department of Endocrinology for nephropathy, defined as a urinary albumin-to-creatinine ratio >30 mg/g.

At baseline, height, body weight, and waist circumference were measured, and body mass index (BMI) was calculated. The body mass index (BMI) was calculated by taking the weight, in kilograms divided by the height in meters squared. A complete physical examination was also performed. In patients evaluated for diabetes mellitus, routinely requested laboratory parameters, including fasting plasma glucose, insulin, HOMA-IR, glycated haemoglobin (HbA1c), complete blood count, liver and renal function tests, erythrocyte sedimentation rate, C-reactive protein (CRP), estimated glomerular filtration rate (eGFR), triglycerides, total cholesterol, HDL, LDL, TSH, and urinary albumin-to-creatinine ratio, were retrieved from the hospital information management system and recorded. Subsequently, all patients were referred to the Faculty of Dentistry, Pamukkale University for further periodontal evaluation.

Following periodontal examination, participants were diagnosed as periodontally healthy, gingivitis, or periodontitis, and were allocated to the corresponding study groups according to their periodontal status. The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop. Periodontally health was considered if the volunteers have clinically healthy gingiva on an intact periodontium who had BOP < 10% and PD ≤ 3 mm, no sites with attachment loss, no radiographic sign of alveolar bone destruction and no history of periodontitis. Gingivitis was characterized by the absence of clinical attachment loss and radiographic bone loss, with a BOP score ≥10% (gingivitis on an intact periodontium). Patients with periodontitis were defined as individuals presenting with periodontal disease characterized by PD ≥6 mm, interdental clinical attachment loss (CAL) ≥5 mm, and radiographic bone loss extending to the middle third of the root or beyond in ≥30% of teeth. In these patients, the number of teeth lost due to periodontitis was ≤4.

In Endocrinology clinic, peripheral venous blood samples were collected from all included participants via the antecubital vein. A total of 10 mL of venous blood was obtained using separator vacutainer tubes and centrifuged at room temperature. Unstimulated whole saliva was collected by passive drooling into a sterile test tube over a 10-minute period in Periodontology clinic. The collected serum and saliva samples were transferred into Eppendorf tubes and stored at -80°C until the day of analysis.

The concentrations of NGAL, TNF-α, and IL-10 in serum and saliva samples were measured using the enzyme-linked immunosorbent assay (ELISA) method at the Department of Histology and Embryology.

The power analyse of the study was performed for sample size calculation. Sample size was calculated using the G*Power software program (G*Power; Universitat, Dusseldorf, Germany) for α = 0.05 and f = 0.4. The analyses revealed that 19 subjects per group achieved a power of 80 % with 95% confidence.

The data were analysed with the SPSS 25 program (SPSS Inc., Chicago, IL). Continuous variables were presented as mean ± standard deviation and categorical variables as numbers and percentages. Shapiro-Wilk test was used to detect data's normality. For the comparison of the parameters of the study groups, One-way ANOVA test was used for normally distributed data while Kruskal-Wallis test was performed as non-parametric test. For pairwise group comparisons, Student's t-test or the Mann-Whitney U test was applied. Chi-square test was used for the comparison of the categorical variables. Statistical significance value was considered as p < 0.05.

Being tested
clinical periodontal measurements, serum samples, saliva samples
Keywords
diabetic nephropathy, periodontitis, NGAL, cytokine, saliva
Medical subject headings
Diabetes Mellitus, Type 2, Periodontitis, Gingivitis, Diabetic Nephropathies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • clinical periodontal measurementsDiagnostic test

    Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.

    the periodontal status of patients was determined based on the Classification of Periodontal and peri-implant diseases and conditions stated in 2017 World Workshop

  • serum samplesDiagnostic test

    Peripheral blood samples were obtained from the antecubital vein. A total of 10 mL of venous blood was collected using separator vacutainer tubes and centrifuged at room temperature. The obtained serum was transferred into separate Eppendorf tubes. The tubes were sealed with parafilm, labeled, and stored at -80°C until the day of analysis.

    NGAL, TNF-alpha and IL-10 levels were analyzed with ELISA method

  • saliva samplesDiagnostic test

    Unstimulated whole saliva samples were collected using the passive drooling method into a sterile collection tube over a 10-minute period.The obtained saliva was transferred into separate Eppendorf tubes. The tubes were sealed with parafilm, labeled, and stored at -80°C until the day of analysis.

    NGAL, TNF-alpha and IL-10 levels were analyzed with ELISA method

Study groups in NCT07498894
Study groupRoleWhat they receive
newly diagnosed type 2 diabetes and periodontal health21 participants with newly diagnosed type 2 diabetes and periodontal health were recruited in group 1. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α.
Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples
newly diagnosed type 2 diabetes and gingivitis20 participants with newly diagnosed type 2 diabetes and gingivitis were recruited in group 2. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α.
Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples
newly diagnosed type 2 diabetes and periodontitis22 participants with newly diagnosed type 2 diabetes and gingivitis were recruited in group 3. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α.
Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples
diabetic nephropathy and periodontal health21 participants with diabetic nephropathy and periodontal health were recruited in group 4. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α.
Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples
diabetic nephropathy and gingivitis20 participants with diabetic nephropathy and gingivitis were recruited in group 5. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α.
Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples
diabetic nephropathy and periodontitis22 participants with diabetic nephropathy and gingivitis were recruited in group 6. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α.
Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. NGAL analysis

    Mean NGAL levels (ng/ml) in serum and saliva

    Measured: baseline

Secondary outcomes (2)
  1. TNF-alpha analysis

    Mean TNF-alpha levels (ng/L)in serum and saliva

    Measured: baseline

  2. IL-10 analysis

    Mean IL-10 levels (ng/ml) in serum and saliva

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2026
  2. Study start10 Jun 2024
  3. Primary completion12 Dec 2025
  4. Study completion12 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
126 participants (actual)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT07498894
Sponsor's protocol ID
2024HZDP005
Status last verified
Mar 2026
First submitted
23 Mar 2026
Last updated
27 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetic Nephropathy Type 2 and Type 2 Diabetes, run by Pamukkale University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

NGAL analysis (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in